SimpliciTB is a multi-centre phase 3 clinical trial evaluating a new shorter drug regimen (all-oral BPaMZ) in drug susceptible and resistant pulmonary tuberculosis across 4 continents led by TB Alliance. The trial started in 2018 and the European and Developing Countries Clinical Trials Partnership (EDCTP) has recently awarded 12 million euro for the execution of the trial in sub-Saharan Africa. It also includes capacity building funding that will enhance clinical research in these settings. The University of St Andrews will coordinate the grant and lead medical monitoring, and the TB Alliance will work with PanACEA clinical research sites of PanACEA to deliver the trial.
We are excited that a significant component of the grant is dedicated to building clinical trials capacity in PanACEA sites in line with PanACEA’s objective to support the consortium to deliver improved treatments for patients with tuberculosis.